Biotechnology News and Research

RSS

Fenwal biomedical engineer receives prestigious Junior Investigator Award for research on photopheresis

Fenwal, Inc., a global medical technology company focused on improving blood collection, separation, safety and availability, announced today that on Friday, May 29, 2010, the American Society for Apheresis will present Fenwal biomedical engineer Katherine Radwanski with the prestigious Junior Investigator Award for her research on photopheresis.

28 May 2010

InNexus Biotechnology announces research Collaboration Agreement with National Cancer Institute

InNexus Biotechnology Inc., a drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL™) technology, today announced the Company has entered into a Collaboration Agreement with the National Cancer Institute (NCI) of the U.S. National Institutes of Health (NIH) to research proprietary technologies developed by InNexus.

28 May 2010

Hamilton Thorne announces vendor partnership agreement with Leica Microsystems

Hamilton Thorne Ltd., a leading provider of advanced laser systems and instruments for the stem cell research and fertility clinic markets, today announces a vendor partnership agreement with Leica Microsystems GmbH of Wetzlar, Germany, a leading global designer and producer of innovative high-tech precision optics systems for the analysis of microstructures.

28 May 2010

Applied Biocode receives CE Certified marking for BioCode-1000 Analyzer

Applied BioCode, Inc. announced that its BioCode-1000 Analyzer has been CE Certified under the compliance of Laboratory Equipment Standards EN55011, EN61010-1, EN61326-1, IEC61010, EN61000-3-2, and EN61000-3-3. The CE Certified marking that the BioCode-1000 Analyzer has met all relevant European Union consumer safety requirements.

28 May 2010

ARCA receives approval to begin enrollment of first therapeutic trial with GeoVax vaccine

GeoVax Labs, Inc., a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines, announced today The AIDS Research Consortium of Atlanta has received approval to begin enrollment of the first therapeutic trial ever conducted using a promising HIV vaccine candidate from GeoVax, Inc.

28 May 2010

NOXXON Pharma closes €33 million Series D round of financing

NOXXON Pharma AG, a company focused on the development of mirror image oligonucleotide therapeutics called Spiegelmers®, announced today the successful closing of a €33 million Series D round of financing. The round was led by new investor, NGN Capital, and joined by existing investors TVM Capital, Sofinnova Partners, Edmond de Rothschild Investment Partners, Seventure Partners, VC Fonds Technologie Berlin GmbH, Dow Venture Capital, FCP OP MEDICAL BioHealth-Trends, IBG Beteiligungsgesellschaft Sachsen-Anhalt mbH, the Dieckell Group, and others.

27 May 2010

National Science Foundation supports PolyMedix with $150,000 grant for development of antimicrobial sutures

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat serious acute cardiovascular disorders and infectious diseases, has received a grant in the amount of $150,000 from the National Science Foundation to support the development of antimicrobial sutures. PolyMedix has developed a series of novel antimicrobial polymers for device and material applications, which it collectively calls the PolyCides™.

27 May 2010

Pressure BioSciences signs CRADA with AFIP, ARP and VA

Pressure BioSciences, Inc. today announced that it has signed a Cooperative Research and Development Agreement ("CRADA") with the Armed Forces Institute of Pathology ("AFIP"), the American Registry of Pathology ("ARP"), and the Department of Veterans Affairs ("VA").

27 May 2010

SonoSite signs agreement to acquire privately held Visualsonics

SonoSite, Inc., the world leader and specialist in bedside and point-of-care ultrasound, today announced that it has signed an agreement to acquire privately held Visualsonics, a Toronto-based company focused on ultra high-frequency micro-ultrasound technology. The aggregate transaction value will be approximately $71 million net of cash and debt.

27 May 2010

FDA, EMA approve Repligen's proposal for Phase 3 re-read in RG1068 trial for pancreatic imaging

Repligen Corporation announced today that the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have approved the Company's proposal to re-analyze the images from our Phase 3 study to establish the utility of RG1068, synthetic human secretin, in improving magnetic resonance imaging (MRI) of the pancreas (Phase 3 re-read).

27 May 2010

Naturxan expands production and distribution capabilities to provide worldwide availability of Aquasta

Naturxan, LLC, a joint venture between Archer Daniels Midland Company and Igene Biotechnology, Inc., today announced that it has completed an expansion of its production and distribution capabilities to provide worldwide availability of Aquasta, a naturally sourced astaxanthin made from Phaffia yeast for enriching and pigmenting salmon and trout consuming aquaculture feeds.

27 May 2010

Space Shuttle Atlantis returns from International Space Station with tenth scientific payload for Astrogenetix

Space Shuttle Atlantis returned from the International Space Station (ISS) landing at the Kennedy Space Center this morning with the tenth scientific payload for Astrogenetix, a commercial biotech company based out of Austin, Texas. Astrogenetix is conducting research on methicillin-resistant Staphylococcus aureus (MRSA) as part of the ISS National Laboratory Pathfinder Vaccine (NLP-V) missions.

27 May 2010

New multidisciplinary task force to help clients identify, evaluate opportunities created by health care reform

Drawing on its analysis of the historic Patient Protection and Affordable Care Act of 2010, Squire, Sanders & Dempsey L.L.P. has established a multidisciplinary task force to help clients identify and evaluate key opportunities created by health care reform.

27 May 2010

Important milestone in development of ORMD-0801 published in DOM journal

Oramed Pharmaceuticals Inc., a developer of alternative drug delivery systems, announced today that the paper entitled, "Open-label study to assess the safety and pharmacodynamics of five oral insulin formulations in healthy subjects," authored by Dr. Roy Eldor, Dr. Miriam Kidron and Dr. Ehud Arbit, was accepted and published in the Diabetes, Obesity and Metabolism journal.

26 May 2010

CTRC starts enrolment in Phase 2 combination trial of REOLYSIN and gemcitabine for advanced pancreatic cancer

Oncolytics Biotech Inc. announced today that the Cancer Therapy & Research Center at the University of Texas Health Science Center in San Antonio (CTRC) has started patient enrolment in a U.S. Phase 2 clinical trial using intravenous administration of REOLYSIN(R) in combination with gemcitabine (Gemzar(R)) in patients with advanced pancreatic cancer. The Principal Investigator is Dr. Monica Mita of the CTRC.

26 May 2010

Report: 235 new medicines in development to treat diabetes

A record 235 new medicines to treat diabetes, one of the fastest-growing diseases in America, are being developed by America's pharmaceutical research and biotechnology companies, according to a national report unveiled today in Charleston.

26 May 2010

Silence Therapeutics deepens diverse portfolio of RNAi intellectual property

Silence Therapeutics plc announces the issuance of United States patent 7,723,316, titled Compositions and Methods of RNAi Therapeutics For Treatment of Cancer and Other Neovascularization Disease, by the United States Patent and Trademark Office (USPTO).

26 May 2010

Research findings on pediatric ILD published online in PED

An insightful and in-depth presentation of the most up-to-date clinical and research findings and historical perspectives on pediatric interstitial lung disease is presented in a special issue published online ahead of print in Pediatric Allergy, Immunology, and Pulmonology, a peer-reviewed journal published by Mary Ann Liebert, Inc.

26 May 2010

Vertex reports 75% patients with HCV achieve viral cure with 12-week telaprevir-based combination regimen

Vertex Pharmaceuticals Incorporated today announced that 75% of people chronically infected with genotype 1 hepatitis C virus (HCV) who had not previously been treated achieved a sustained viral response (SVR or viral cure) after receiving a 12-week telaprevir-based combination regimen, followed by treatment with pegylated-interferon and ribavirin alone, in the Phase 3 ADVANCE trial.

26 May 2010

AMRI to reduce US workforce by 10%

AMRI today announced that it is repositioning itself to meet a continued shift in demand from customers for services in Asia and Europe. Overall for 2009 and 2010, the company anticipates investing in excess of $30 million on international facility and capability expansions and estimates its non-US workforce will increase by approximately 180 positions in order to meet known and anticipated customer demand.

26 May 2010

Biotechnology News and Research

Fenwal biomedical engineer receives prestigious Junior Investigator Award for research on photopheresis

InNexus Biotechnology announces research Collaboration Agreement with National Cancer Institute

Hamilton Thorne announces vendor partnership agreement with Leica Microsystems

Applied Biocode receives CE Certified marking for BioCode-1000 Analyzer

ARCA receives approval to begin enrollment of first therapeutic trial with GeoVax vaccine

NOXXON Pharma closes €33 million Series D round of financing

National Science Foundation supports PolyMedix with $150,000 grant for development of antimicrobial sutures

Pressure BioSciences signs CRADA with AFIP, ARP and VA

SonoSite signs agreement to acquire privately held Visualsonics

FDA, EMA approve Repligen's proposal for Phase 3 re-read in RG1068 trial for pancreatic imaging

Naturxan expands production and distribution capabilities to provide worldwide availability of Aquasta

Space Shuttle Atlantis returns from International Space Station with tenth scientific payload for Astrogenetix

New multidisciplinary task force to help clients identify, evaluate opportunities created by health care reform

Important milestone in development of ORMD-0801 published in DOM journal

CTRC starts enrolment in Phase 2 combination trial of REOLYSIN and gemcitabine for advanced pancreatic cancer

Report: 235 new medicines in development to treat diabetes

Silence Therapeutics deepens diverse portfolio of RNAi intellectual property

Research findings on pediatric ILD published online in PED

Vertex reports 75% patients with HCV achieve viral cure with 12-week telaprevir-based combination regimen

AMRI to reduce US workforce by 10%

Event guide: 3rd IMPACCT Real World Evidence Summit Europe eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News